Our Partners

Ambrilia has high regard for partnerships because they support and add-value to activities both inside and outside its value chain. Accordingly, the Company cultivates relationships with quality partners who are experts in their respective field, such as clinical development, manufacturing and commercialization. Ambrilia’s current partners are:

C2L (Octreotide): Acromegaly and Carcinoid Tumors – Phase III

Licensing Partners: Gerolymatos (Greece, Turkey and other countries), Kwidza Pharma (Austria), Omega (Canada, Egypt), Pharmis (Portugal, Brazil), Genepharm Limited (Australia and New Zealand) and Shin Poong (Korea).

Manufacturing Partners and main Suppliers: Lakeshore Biomaterial, PolyPeptides

Other - Colopath®/ColorectAlert™: Diagnosis of Colorectal Cancer

Worldwide Licensing Partner: PreMD Inc.


\

 

Financial Reports